On Wednesday, Organon & Co (OGN) stock saw a modest uptick, ending the day at $15.61 which represents a slight increase of $0.03 or 0.19% from the prior close of $15.58. The stock opened at $15.58 and ...

In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

CWA Asset Management Group LLC acquired a new position in Organon & Co. (NYSE:OGN – Free Report) in the third quarter, ...

Incaier, the healthcare arm of Haier Group, has participated in the expo for five consecutive years. This year, more than 50 ...

Havas Health named Anna Maria Marra as CEO of Europe on Tuesday morning, a role in which she will lead and oversee all ...

Pfizer hired Marra all the way back in 2002, at which time the new Havas Health exec had spent a few years working at Merck ...

MAPS 2025 Americas Annual Meeting Annual meeting sessions aligned with MAPS Medical Affairs Competencies Framework provide training oppo ...

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Organon & Co. (OGN) on Thursday reported third-quarter profit of $359 million. On a per-share basis, the Jersey City, New Jersey-based company ...

Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found ...

Organon Philippines, a women’s health company, recently unveiled its Her Health Finder, an online tool that aims to empower ...

On October 30, 2024, Shanghai Henlius Biotech and Organon announced that the FDA has accepted the Biologic License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA (denosumab). In ...

Organon's OGN short percent of float has risen 28.4% since its last report. The company recently reported that it has 12.53 ...